On the contrary, the observed reduction in the PARPi efficacy after treatment with taxol in the BRCA1-deficient ovarian cancer uWB1.289 cell line would argue against the combined treatment of olaparib with paclitaxel, where olaparib has already been shown to not increase the efficacy of treatment with paclitaxel and carboplatinum59,60. This evidence concerns the gene BRCA1 and ovarian cancer.